Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

724 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, Tuomiranta T, Hannonen P, Paimela L; ONCE trial group. Hakala M, et al. Among authors: kroger h. Scand J Rheumatol. 2012 Aug;41(4):260-6. doi: 10.3109/03009742.2012.664647. Scand J Rheumatol. 2012. PMID: 22803768 Clinical Trial.
[Bone density reference values in Finnish women].
Kröger H, Huopio J, Heikkinen J, Laitinen K, Kotaniemi A. Kröger H, et al. Duodecim. 1993;109(7):578-84. Duodecim. 1993. PMID: 8062728 Finnish. No abstract available.
Associations of genetic lactase non-persistence and sex with bone loss in young adulthood.
Laaksonen MM, Impivaara O, Sievänen H, Viikari JS, Lehtimäki TJ, Lamberg-Allardt CJ, Kärkkäinen MU, Välimäki M, Heikkinen J, Kröger LM, Kröger HP, Jurvelin JS, Kähönen MA, Raitakari OT; Cardiovascular Risk in Young Finns Study Group. Laaksonen MM, et al. Among authors: kroger hp, kroger lm. Bone. 2009 May;44(5):1003-9. doi: 10.1016/j.bone.2008.12.019. Epub 2009 Jan 3. Bone. 2009. PMID: 19168163
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E. Välimäki MJ, et al. Among authors: kroger h. Clin Ther. 2007 Sep;29(9):1937-49. doi: 10.1016/j.clinthera.2007.09.017. Clin Ther. 2007. PMID: 18035193 Clinical Trial.
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD; Bazedoxifene Study Group. Silverman SL, et al. Osteoporos Int. 2012 Jan;23(1):351-63. doi: 10.1007/s00198-011-1691-1. Epub 2011 Jul 21. Osteoporos Int. 2012. PMID: 21779819 Clinical Trial.
724 results